$31.37
+0.17 (+0.54%)
CVI News8 articles
Sumitomo Electric's Rally Raises Fair Value Questions Amid Pullback
Sumitomo Electric stock surged 300% in 12 months but pulled back 15.7% last week, trading near its DCF fair value of ¥10,975. CVR Energy and Icahn Enterprises also show mixed valuation signals.
AtaiBeckley Shares Steady at $7.17 as CVR Valued at 42 Cents in Lilly Deal
AtaiBeckley shares remain flat at $7.17, 42 cents above Eli Lilly's cash offer, with the contingent value rights (CVR) implied at 16.8% of the $2.50 maximum payout.
AtaiBeckley Shares Reflect Merger CVR Valued at 19% of Par
AtaiBeckley shares surged 39.7% last week to $7.22, with the merger CVR valued at $0.47, representing 18.8% of its $2.50 maximum payout.
AtaiBeckley Merger Value Reflects 14% of CVR Face Value
AtaiBeckley shares trade at $7.091, 34 cents above Eli Lilly's cash offer, implying a CVR value of 13.6% of its maximum $2.50 face value.
Centessa's Final Trade Values Eli Lilly CVR at 28 Cents on the Dollar
Centessa's final trade at $40.50 values Eli Lilly's $9 contingent value right at $2.50, or 27.8 cents per dollar, as the acquisition closes and ADS trading halts.
Centessa's Final Trade Puts Lilly CVR at 28% of Maximum Value
Centessa's final $40.50 trade implies a 28% value on its non-transferable CVR from the $38/share Lilly buyout, with only drug-approval payouts remaining.
Apellis Delisted After Biogen Buyout; CVR Payout in Focus
Apellis Pharmaceuticals has been delisted from Nasdaq following Biogen's completed acquisition. Shareholders get $41 per share plus a contingent value right worth up to $4 if Syfovre meets sales goals.
Biogen Closes Apellis Takeover; CVR Offers Upside
Biogen completed its $41/share cash acquisition of Apellis, delisting the stock from Nasdaq. Shareholders also received a contingent value right that could pay up to $4 if Syfovre sales hit targets.